Literature DB >> 15997419

The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

H Bartosik-Psujek1, Z Stelmasiak.   

Abstract

Total-tau protein is considered the marker of axon damage whereas the abnormally phosphorylated tau forms are mainly associated with Alzheimer's disease. An increase in total-tau levels was observed in neurodegenerative diseases, including multiple sclerosis (MS). In order to find out whether the phosphorylated tau forms occur in MS patients and to evaluate their clinical significance, the levels of total-tau (t-tau) and tau phosphorylated at Thr 181 (p-tau) were determined in 60 MS patients (40 during relapse including 18 with the first relapse and 20 stable) and in 18 age-matched controls. The determinations were conducted in the cerebrospinal fluid (CSF) using the ELISA method. The levels of t-tau and p-tau were higher in MS patients than in controls; however, increased levels were not related to the clinical activity of the disease. In CSF of the patients with the first relapse the level of t-tau was significantly increased whilst the level of p-tau was not elevated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997419     DOI: 10.1007/s00702-005-0327-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.

Authors:  Halina Bartosik-Psujek; Juan J Archelos
Journal:  J Neurol       Date:  2004-04       Impact factor: 4.849

2.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

Authors:  K Blennow; A Wallin; H Agren; C Spenger; J Siegfried; E Vanmechelen
Journal:  Mol Chem Neuropathol       Date:  1995-12

3.  Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Authors:  F Hulstaert; K Blennow; A Ivanoiu; H C Schoonderwaldt; M Riemenschneider; P P De Deyn; C Bancher; P Cras; J Wiltfang; P D Mehta; K Iqbal; H Pottel; E Vanmechelen; H Vanderstichele
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

4.  Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.

Authors:  Thomas Fath; Jochen Eidenmüller; Roland Brandt
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

5.  CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

Authors:  L Parnetti; A Lanari; S Amici; V Gallai; E Vanmechelen; F Hulstaert
Journal:  Neurol Sci       Date:  2001-02       Impact factor: 3.307

6.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

Authors:  M Riemenschneider; S Wagenpfeil; H Vanderstichele; M Otto; J Wiltfang; H Kretzschmar; E Vanmechelen; H Förstl; A Kurz
Journal:  Mol Psychiatry       Date:  2003-03       Impact factor: 15.992

7.  Cerebrospinal fluid tau levels increase with age in healthy individuals.

Authors:  M Blomberg; M Jensen; H Basun; L Lannfelt; L O Wahlund
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Mar-Apr       Impact factor: 2.959

8.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

9.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

Authors:  Alessia Maddalena; Andreas Papassotiropoulos; Britta Müller-Tillmanns; Hans H Jung; Thomas Hegi; Roger M Nitsch; Christoph Hock
Journal:  Arch Neurol       Date:  2003-09

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  8 in total

Review 1.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

Review 3.  Cognitive Decline in Older People with Multiple Sclerosis-A Narrative Review of the Literature.

Authors:  Hsueh-Sheng Chiang; Alka Khera; Barbara E Stopschinski; Olaf Stuve; John Hart; Brendan Kelley; Trung Nguyen
Journal:  Geriatrics (Basel)       Date:  2022-06-05

Review 4.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  CSF phospho-tau is independent of age, cognitive status and gender of neurological patients.

Authors:  Armin Scheurich; Peter P Urban; Nassrin Koch-Khoury; Andreas Fellgiebel
Journal:  J Neurol       Date:  2009-11-17       Impact factor: 4.849

6.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

7.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Authors:  Edward N Wilson; Michelle S Swarovski; Patricia Linortner; Marian Shahid; Abigail J Zuckerman; Qian Wang; Divya Channappa; Paras S Minhas; Siddhita D Mhatre; Edward D Plowey; Joseph F Quinn; Cyrus P Zabetian; Lu Tian; Frank M Longo; Brenna Cholerton; Thomas J Montine; Kathleen L Poston; Katrin I Andreasson
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

8.  A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis.

Authors:  David Wheeler; Veera Venkata Ratnam Bandaru; Peter A Calabresi; Avindra Nath; Norman J Haughey
Journal:  Brain       Date:  2008-09-04       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.